Physician profile
Raviprasad Subraya
NPI 1205838596
$3,964.66
in general payments reported to CMS, 2019-2025
32 companies · $602 in 2025
The $602 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $517 · 2021: $901 · 2022: $333 · 2023: $385 · 2024: $775 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $608.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $559.71 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $453.16 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $435.26 | 2024-2025 | Assure Wcd |
| Heartflow, INC. | $196.57 | 2024-2025 | |
| Boston Scientific Corporation | $165.45 | 2019-2025 | Avvigo Guidance System |
| Abiomed | $163.09 | 2024-2025 | Impella |
| Esperion Therapeutics, INC. | $158.58 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.39 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $97.87 | 2022 | |
| Cook Medical LLC | $94.56 | 2020 | |
| Bard Peripheral Vascular, INC. | $90.11 | 2021 | |
| Merck Sharp & Dohme LLC | $79.40 | 2023-2025 | Verquvo |
| Baxter Healthcare | $78.11 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Atricure, INC. | $75.61 | 2024-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.33 | 2021-2022 | |
| Abbott Laboratories | $61.83 | 2021-2025 | Ensite Precision |
| Cvrx, INC. | $58.06 | 2022-2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $56.38 | 2019-2023 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $42.34 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $38.30 | 2020-2021 | |
| Biotronik INC. | $36.31 | 2019 | |
| Portola Pharmaceuticals, LLC | $30.83 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $28.35 | 2021 | |
| Glaxosmithkline, LLC. | $24.69 | 2025 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $18.82 | 2019 | |
| Edwards Lifesciences Corporation | $17.99 | 2019 | |
| Scpharmaceuticals INC. | $15.40 | 2024 | |
| Pfizer INC. | $14.85 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $12.95 | 2023 | Inpefa |
| Arbor Pharmaceuticals, INC. | $12.69 | 2019 | |
| Bardy Diagnostics, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raviprasad Subraya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.